Amgen looking for acquisitions

Feb 11, 2018

Financial Times

Amgen says it is “looking hard” for a deal, but is struggling to find the right target, reports Financial Times.

The drugmaker says it has refrained from bidding on recent deals because it hasn’t been able to come up with a business case that would yield a return for shareholders.

“We want to deploy any excess cash and our first priority is to do acquisitions and invest in the business,” David Meline, Amgen’s CFO, told the Financial Times.

Meline added that Amgen has a lot of “financial flexibility” -- $27bn of available cash -- and will continue to keep looking.

Read the Financial Times article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments